Consequently, it has been shown that the EGFR muta-tion is correlated with the non-small-cell lung cancer patients' response to therapy, such as Erlotinib and Gefitinib, as EGFR inhibitors (20–22). Here, EGFR is linked to non-small cell lung carcinoma.